2019: Key Takeaways for Market Access Leaders
As the year comes to a close, 2019 may be just as notable for changes that didn’t happen as much as for those that did.
For much of 2019, the federal government focused on high drug prices and transparency, with legislation introduced that impacted manufacturers and payers. While there was a lot of movement in the beginning of 2019, the end of the year saw few noteworthy policies pass into law. This issue, we asked our advisors to reflect on the market events in 2019 by type of payer. Todd Edgar assesses what didn’t happen; Dan Danielson examines the impact of potential regulations on regional health plans; Andy Cournoyer reviews key national health plan events; and Ryan Cox and Erin Lopata team up to bring us noteworthy health system and IDN trends.
All Access is produced specifically to help you navigate the payer landscape. Thanks for the topic suggestions for our team of ex-payers, please enjoy this edition and may your holiday season be filled with joy!
Charline Shan, RPh, MPH
Vice President, Access Experience Team
All Access is a bimonthly newsletter that features key insights from our team of former payers, intended specifically for market access leaders. It is published by Precision for Value.
The most important events in healthcare in 2019 were the ones that didn’t happen. Access Experience Team member Todd Edgar explains why, with a focus on drug pricing and policy proposals.
Dan Danielson examines the impact of 2019 policy proposals changes on regional health plans, and notes that uncertainty from stakeholders has created the need for manufacturers to provide concise messaging that emphasizes value to payers.
Access Experience Team member Andrew Cournoyer looks at national health plans and the growing trend toward vertical integration and management of drugs covered under the medical benefit.
Team members Ryan Cox and Erin Lopata examine consolidation among health systems. Will this trend lead to lower costs and better care or should stakeholders be more concerned with the growing power of the industry heavyweights?